Clinical and Translational Science Institute

Centers

5-23-2018

Impact of diffuse large B-cell lymphoma on visits to different
provider specialties among elderly Medicare beneficiaries:
challenges for care coordination
Rahul Garg
West Virginia University

Usha Sambamoorthi
West Virginia University

Xi Tan
West Virginia University

Soumit K. Basu
University of Louisville

Treah Haggerty
West Virginia University

See
next
page
additional
authors
Follow
this
andfor
additional
works
at: https://researchrepository.wvu.edu/ctsi
Part of the Medicine and Health Sciences Commons

Digital Commons Citation
Garg, Rahul; Sambamoorthi, Usha; Tan, Xi; Basu, Soumit K.; Haggerty, Treah; and Kelly, Kimberly M.,
"Impact of diffuse large B-cell lymphoma on visits to different provider specialties among elderly
Medicare beneficiaries: challenges for care coordination" (2018). Clinical and Translational Science
Institute. 944.
https://researchrepository.wvu.edu/ctsi/944

This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

Authors
Rahul Garg, Usha Sambamoorthi, Xi Tan, Soumit K. Basu, Treah Haggerty, and Kimberly M. Kelly

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/ctsi/944

TBM

ORIGINAL RESEARCH

Impact of diffuse large B-cell lymphoma on visits to different
provider specialties among elderly Medicare beneficiaries:
challenges for care coordination
Rahul Garg,1 Usha Sambamoorthi,1 Xi Tan,1 Soumit K. Basu,2 Treah Haggerty,3
Kimberly M. Kelly1,4
1

Department of Pharmaceutical
Systems and Policy, School of
Pharmacy, West Virginia University,
Morgantown, WV 26506, USA
2
James Graham Brown Cancer
Center, University of Louisville,
Louisville, KY 40208, USA
3
Department of Family Medicine,
School of Medicine, West Virginia
University, Morgantown, WV
26506, USA
4
Mary Babb Randolph Cancer
Center, West Virginia University,
Morgantown, WV 26506, USA

Correspondence to: KM Kelly,
kmkelly@hsc.wvu.edu
Cite this as: TBM 2018;8:386–399
doi: 10.1093/tbm/ibx071
© Society of Behavioral Medicine
2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Abstract
Newly diagnosed diffuse large B-cell lymphoma (DLBCL) can
pose significant challenges to care coordination. We utilized
a social-ecological model to understand the impact of DLBCL
diagnosis on visits to primary care providers (PCPs) and specialists, a key component of care coordination, over a 3-year
period of cancer diagnosis and treatment. We used hurdle models and multivariable logistic regression with the Surveillance
Epidemiology and End Result-Medicare linked dataset to
analyze visits to PCPs and specialists by DLBCL patients (n =
5,455) compared with noncancer patients (n = 14,770). DLBCL
patients were more likely to visit PCPs (adjusted odds ratio,
AOR [95% confidence interval, CI]: 1.25 [1.18, 1.31]) and had
greater number of visits to PCPs (β, SE: 0.384, −0.014) than
noncancer patients. Further, DLBCL patients were more likely
to have any visit to cardiologists (AOR [95% CI]: 1.40 [1.32,
1.47]), endocrinologists (1.43, [1.21, 1.70]), and pulmonologists (1.51 [1.36, 1.67]) than noncancer patients. Among
DLBCL patients, the number of PCP visits markedly increased
during the treatment period compared with the baseline period
(β, SE: 0.491, −0.028) and then decreased to baseline levels
(−0.464, −0.022). Visits to PCPs and specialists were much
more frequent for DLBCL patients than noncancer patients,
which drastically increased during the DLBCL treatment period
for chronic care. More chronic conditions, treatment side effects,
and frequent testing may have increased visits to PCPs and
specialists. Interventions to improve care coordination may
need to target the DLBCL treatment period, when patients are
most vulnerable to poor care coordination.
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INTRODUCTION

Non-Hodgkin’s lymphoma (NHL) is the most prevalent blood cancer with approximately 72,580 new
cases of NHL expected to be diagnosed in 2016
[1]. Diffuse large B-cell lymphoma (DLBCL) is the
most common subtype of NHL (30%–58%) and commonly occurs in adults above 64 years of age [2].
Approximately 27,650 new cases of DLBCL were
diagnosed in the USA in 2016, with a higher rate in
males (8.4 per 100,000 individuals) compared with
females (5.6 per 100,000 individuals) [3]. The survival
rates for DLBCL were highest for White females and

Implications

Practice: Primary and chronic care of DLBCL
patients should not be neglected during the
cancer treatment and follow-up periods as
DLBCL patients may have higher chronic care
needs than noncancer patients. Furthermore,
DLBCL patients at risk for mental illness should
be referred to suitable mental health specialists
when necessary.
Policy: Policymakers who want to improve care
coordination for cancer patients may need to
target the cancer treatment period.
Research: Future studies need to investigate the
cancer patients’ perceived barriers to care coordination among their primary care providers,
oncologists, and specialists.

lowest for Black males (2 years: 63%–68%, 5 years:
55%–62%, and 10 years: 48%–55%) [3]. DLBCL can
lead to secondary cancers [4], posttraumatic stress
[5], and poor quality of life in patients diagnosed with
DLBCL [6]. Furthermore, 82.0% of older adults have
pre-existing chronic physical or mental health conditions [7, 8]. Therefore, individuals diagnosed with
DLBCL receive care from multiple providers such as
the oncologists, primary care physicians (PCPs), and
other medical specialists (e.g., cardiologist, endocrinologists, psychologists, and others). Although
not specific to DLBCL, older adults visit an average
of six different providers in a year [9]. Previous studies have found that under the fee-for-service system,
the receipt of uncoordinated care from multiple
providers can lead to medication errors [10], duplication of services [11], emergency room visits [12],
unplanned hospital readmissions [13], increased
costs [11, 14], preventable hospitalizations [14] and
ultimately worsening patient health [15]. In its report
on cancer survivorship, the National Academy of
Medicine (formerly called the Institute of Medicine)
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recommended that individualized survivorship care
plans should be developed to increase care coordination for cancer patients. The U.S. Department of
Health and Human Services [16] and the National
Quality Forum [17] have also developed strategic
frameworks of care to identify novel models of care
and include effective care coordination as one of the
care quality measures.
Care coordination may be further compromised
with newly diagnosed cancer [11] because cancer
patients need care from multiple providers for
their chronic conditions and cancer. For example,
among breast cancer patients, visits to oncologists
and PCPs increased after breast cancer diagnosis
[18–20]. Colorectal cancer patients had more visits
to PCPs after the treatment period compared with
the prediagnosis period [21, 22]. These findings
suggest that cancer patients may be receiving care
from both oncologists and PCPs. However, DLBCL
patients may consult their PCPs or other medical
specialists for symptoms before being referred to
an oncologist because they may experience vague
symptoms such as painless swelling of lymph nodes,
fever, and weight loss [23]. The visits to PCPs and
other medical specialists may continue during and
after the cancer treatment period because, unlike
other cancers, DLBCL can affect multiple organs
[24]. In a cross-sectional survey conducted among
NHL patients, 87.1% visited PCPs or other medical specialists, in addition to their oncologists
[25]. However, the investigators did not examine
provider visits by patients with DLBCL which is
markedly different in treatment and survival prognosis from other subtypes of NHL [2]. DLBCL is
an aggressive form of NHL and is often treated
with intense therapeutic regimens such as stem cell
transplant [26, 27]. It is possible that an aggressive treatment of DLBCL can either increase or
decrease the visits to PCPs and other medical specialists. For example, DLBCL treatment can worsen
other chronic conditions, or patients may have
new diagnoses of chronic conditions, leading to an
increase in PCP visits. However, it is also possible
that due to prioritization of cancer care, DLBCL
patients may not continue to see their PCPs or
other medical specialists, specifically during the
cancer treatment period [28]. This study will clarify
the impact of an aggressive cancer such as DLBCL
on change in primary and specialist visits and the
associated care coordination challenges among
them. To the best of our knowledge, no study has
investigated whether DLBCL affects visits to PCPs
and other medical specialists, an indicator of care
coordination. It is important to examine DLBCL
patients’ visits to PCPs because cancer follow-up
care in primary care settings is cost-effective [29].
While oncologists are responsible for the treatment
of cancer, they may be less effective than PCPs and
other medical specialists in providing care for other
chronic conditions [30].
TBM

Theoretical framework

DLBCL patients’ visits to different providers can be
influenced by patients’ personal characteristics as
well as external social and healthcare environmental factors. These multiple levels of influence on an
individual’s health behavior can be best understood
by using the social-ecological model (SEM) of health
behavior [31]. The SEM is an ecological model,
which seeks to incorporate the multilevel factors
that influence health behavior and the interaction of
these factors. Including concepts at the macro level,
such as the community, and at the micro level, such
as individual biology or psychology, the SEM is capable of incorporating a diversity of models at the individual, organizational, and environmental levels to
better understand whether an individual will engage
in a behavior. This model is well suited to the context
of care coordination, as factors such as the patient’s
disease state and the larger healthcare system play a
role in the treatment that a patient receives.
We utilized the SEM to examine factors associated with visits to PCPs and other medical specialists [31], including (a) intrapersonal factors: patient’s
socio-demographic characteristics, chronic conditions, and cancer treatments received; (b) healthcare
system factors: density of physicians and facilities;
and (c) community factors: region, urbanacity, area
poverty, area education, and formal and informal
social support systems [32–34]. We used a nationally
representative linked dataset of cancer registries and
Medicare claims in the USA. The primary objective
of this study was to evaluate the impact of newly
diagnosed DLBCL on visits to PCPs and other medical specialists among the elderly Medicare beneficiaries compared with those without any cancer.
The secondary objective was to examine the change
in PCP visits and use of medical specialists before
and after DLBCL diagnosis.
METHODS
Study design

We utilized a retrospective longitudinal design with
12-month preindex and 24-month postindex periods. Because provider visits may increase among
older adults with DLBCL for noncancer reasons
such as an increase in age and chronic conditions, we
included a comparison group of noncancer patients
to examine the impact of DLBCL on change in provider visits over time. This is a stronger study design
than those currently in the literature.
For the DLBCL patients, pre- and postindex periods were identified using the DLBCL diagnosis date
as the index date. For the noncancer patients, preand postindex periods were derived using randomly
selected dates of service from inpatient or outpatient
Medicare claims. The DLBCL treatment period lasts
for approximately 6 months [2]. Hence, the pre- and
postindex periods were divided into six equal time
intervals of 6 months each. For DLBCL patients, the
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preindex period included baseline (T1) and prediagnosis (T2) and postindex period comprised treatment (T3), posttreatment (T4), short follow-up (T5),
and long follow-up (T6) periods.
Data sources

We used data from following sources: (a) Surveillance
Epidemiology and End Results (SEER)—Medicare
database; (b) 5% Medicare sample for patients without any cancer; and (c) Area Health Resource File
(AHRF). The SEER is a comprehensive database of
20 population-based tumor registries in the USA that
collects information for all the newly diagnosed cancer cases such as demographics, cancer site, date of
cancer diagnosis, and cancer pathology (e.g., stage
and grade) [35]. The SEER mortality data are provided by the National Center for Health Statistics, and
the epidemiological data on cancer rates are derived
periodically from the Census Bureau [35]. The SEERMedicare linked data include cancer patients, who are
also enrolled in Medicare. Medicare is the primary
health insurer for a majority of adults aged 65 years
and older in the USA [36]. About 93% of patients
in SEER with age 65 years and above are matched
with their Medicare enrollment files by the National
Cancer Institute and the Centers for Medicare and
Medicaid Services [37]. The Medicare claims of cancer patients can be used to derive detailed information
on medical treatment, chronic conditions, healthcare
utilization, and expenditures. We used Medicare data
from the following files: Medicare Provider Analysis
and Review (MEDPAR—inpatient data), Outpatient
Standard Analytical Files (SAF—outpatient data),
carrier claims (physician claims data), Home Health
Agency (HHA—home health services), and durable
medical equipment (DME—medical equipment use)
to measure provider visits, chronic conditions, and
DLBCL treatments in this study [36]. The noncancer cohort was derived from a random 5% sample of
Medicare beneficiaries residing in the SEER areas.
Individuals in the 5% sample who are also present in
the SEER cancer cohort are removed to obtain a random sample of noncancer cases [35, 37].
The AHRF is a publicly available data file provided
by the Department of Health and Human Services
which contains information on more than 6,000 variables for each of the U.S. counties [38]. The AHRF
contains data on the availability of health professionals, healthcare facilities, and socioeconomic and environmental characteristics of each county. We used
the state and county Federal Information Processing
Standard (FIPS) codes to link the AHRF files with the
SEER-Medicare dataset to measure the county-level
healthcare system and community factors.
Study population

The DLBCL was identified using the International
Classification of Diseases for Oncology—Third
Revision (ICD-O-3)/World Health Organization 2008

codes: 13, 14, 15, 16) during 2003–2011. The noncancer patients were derived from a random 5% sample
of Medicare beneficiaries who resided in SEER areas
between 2003 and 2011 and were not diagnosed with
any cancer, except basal cell carcinoma. We selected a
10% random sample of noncancer patients to keep the
ratio of DLBCL to noncancer patients at 1:3, which is
considered optimal for high statistical power [39].
The following exclusion criteria were applied to
both DLBCL population and noncancer sample: (a)
missing values for any demographic factor (e.g., age,
sex, race/ethnicity, and region), (b) not alive during the observation period, (c) less than 66 years of
age, (d) having end-stage renal disease (ESRD), (e)
enrolled in managed care plans, (f) not continuously
enrolled in Medicare parts A and B during the preand postindex periods, and (g) not having any PCP
visit during the entire observation period (Figs. 1
and 2). Additional inclusion criteria were applied to
the DLBCL population: We included individuals if
they had only one primary cancer (except basal cell
carcinoma) and if their cancer was not diagnosed
from autopsy or death certificate.
Measures

Dependent variables
The dependent variables for our study included any
visit to PCPs and other medical specialist. Further,
we analyzed the number of PCP visits among those
with at least one PCP visit. The provider visits were
measured every 180 days (i.e., T1 through T6) and
were derived from the National Claims History
(NCH) files. The PCP specialties included general
practice, family practice, internal medicine, geriatric
medicine, nurse practitioner, or physician assistant
[40]. Visits to other medical specialists included (a)
cardiologists among patients with any heart condition; (b) endocrinologists among patients with diabetes; (c) mental health specialists (psychologist or
psychiatrist) among patients with depression and/
or anxiety; (d) pulmonologists among patients
with asthma or chronic obstructive pulmonary
disease (COPD); and (e) rheumatologists among
patients with arthritis. We identified the specialty
of a physician by using the Health Care Financing
Administration (HCFA) specialty codes. The HCFA
specialty codes from the SEER-Medicare dataset
have been used in previous studies to examine the
role of physician specialty in the care of breast and
colorectal cancer patients [40–42].
Cancer status independent variable
The key independent variable was the presence of
DLBCL versus no cancer, which belonged to the
domain of intrapersonal factors as per SEM.
SEM independent variables
The independent variables in our study included
both time-varying and time invariant variables. The
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Fig. 1 | Flowchart of sample selection for elderly Medicare beneficiaries with diffuse large B-cell lymphoma.

time-varying factors included chronic conditions (arthritis, diabetes, any heart condition, mental condition,
and respiratory condition) and DLBCL treatments
(chemotherapy, radiotherapy, immunotherapy, and
stem cell transplant). The time-varying factors were
measured repeatedly during each time interval from
T1 to T6. All other intrapersonal, healthcare system
and community factors were time invariant and were
measured during 1 year before the index date. All
intrapersonal factors were measured at the individual
level from the SEER-Medicare dataset. The healthcare
system and community factors were measured at the
county level from the AHRF dataset.
Intrapersonal factors
These factors included (a) age at index date (66–
69, 70–74, 75–79, or ≥80 years); (b) sex (male
or female); and (c) race/ethnicity (non-Hispanic
White, non-Hispanic African American, Hispanic,
TBM

or others). Our study examined the impact of
DLBCL on visits to specialists in patients with specific chronic conditions. Hence, we measured individual chronic conditions, instead of a comorbidity
index. We used specific International Classification
of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) diagnosis codes to measure each of
the following chronic conditions during any visit
to PCP or specialist: (a) arthritis (osteoarthritis or
rheumatoid arthritis); (b) diabetes; (c) any heart
condition (cardiac arrhythmia, coronary artery disease, or congestive heart failure); (d) any mental
condition (depression or anxiety); (e) any respiratory condition (asthma or COPD); and (f) DLBCL
stage from the Ann Arbor staging system (Stage I,
II, III, or IV). We used the Healthcare Common
Procedure Coding System (HCPCS) codes, revenue center codes, and ICD-9-CM procedure codes
from Medicare inpatient, outpatient, and physician
page 389 of 399
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Fig. 2 | Flowchart of sample selection for elderly Medicare beneficiaries with no cancer.

claims files to measure the treatments of (a) chemotherapy; (b) radiotherapy; (c) immunotherapy; and
(d) stem cell transplant.
Healthcare system factors
Healthcare system factors were measured at the
county level. These factors included (a) health
professional shortage area for PCPs (whole county,
part of county, or no shortage); (b) quartiles of
average number of hospitals per 10,000 older
adults above 65 years of age (0.56, 0.97, 1.31,
and 3.46); and (c) quartiles of average number
of Federal Qualified Health Centers (FQHC) per
10,000 older adults above 65 years of age (0.01,
0.37, 0.94, and 3.68).

Community factors
Community factors included (a) geographic region
(North-East, South, North-Central, or West); (b)
rurality: We used urban/rural recode to classify
region into metro (counties with <250,000 to 1
million population), urban (counties with 2,500
to >20,000 population), and rural (counties with
<2,500 population); (c) percentage of Blacks; (d) percentage of Hispanics; (e) social or cultural cohesion
measured by percentage of non-English-speaking
individuals above 18 years of age; (f) county percentage of individuals between 18 and 64 years of
age without health insurance (quartiles: 13.10, 17.70,
22.57, and 28.72); (g) county average travel times
to work (quartiles: 19.73, 24.19, 27.44, and 30.95);
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and (h) county percentage of individuals with below
high-school education (quartiles: 8.44, 12.27, 16.31,
and 25.01). In addition to the variables guided by
SEM, we also included time and index year as covariates in all the models.
Statistical analysis

We used chi-square tests to analyze the model-driven
unadjusted differences in intrapersonal, healthcare
system and community factors between DLBCL
and the noncancer patients. Due to multiple levels
of data at county and patient level, the observations
might be correlated. Further, as repeated observations were made for PCP visits from T1 to T6, each
subject was clustered over time as well. To account
for the nonindependence of observations, we used
the population-averaged logistic regression models
(also known as generalized estimating equations—
GEE) with unstructured correlation structure to analyze the relationship between DLBCL and visit to
providers [43]. GEE provide a robust approach to
the analysis of longitudinal and hierarchically clustered data. The main advantage of GEE is in the unbiased estimation of population-averaged regression
coefficients that are robust to any misspecification of
the correlation structure [43].
For change in PCP visits, we used GEE with the
hurdle models to analyze any visit to PCPs and the
number of PCP visits. A hurdle model analyzes
the two processes of generating zeroes and positive
values separately [44]. The first part of the model,
known as “hurdle at zero,” analyzes the occurrence
of an outcome (i.e., PCP visit or no visit). The second
part of the model, known as “above the hurdle,”
analyzes the positive values of the outcome (i.e.,
number of PCP visits above zero) [41]. GEE with
logistic regression was used for the first part, and
GEE with negative binomial regression was used
for second part of the hurdle model. We conducted
regression models with stepwise addition of patientlevel and county-level factors to analyze PCP visits.
We first entered patients’ cancer status (DLBCL vs.
no cancer) followed by the individual-level factors
and then the county-level factors to understand the
association of factors at different hierarchical levels.
Our preliminary analysis indicated that there were
significant differences in characteristics between
the DLBCL and noncancer patients. To reduce this
observed selection bias between the DLBCL and
noncancer patients, we derived inverse probability
treatment weights (IPTW, also known as propensity scores) by conducting a logistic regression on
DLBCL versus no cancer with the following independent variables: sex, race/ethnicity, age, index
year, and chronic conditions. These IPTWs were
used as weights in all the unadjusted and adjusted
analyses [45, 46]. IPTW technique gives weights to
case and control cohorts to create a pseudo-population in which the case assignment (DLBCL or
TBM

noncancer) and covariates are independent of each
other. IPTW weighting technique is considered superior to propensity score matching, which may often
substantially reduce sample size. Hence, study’s
conclusions will only apply to the selected subset
of patients that could be matched [47]. All analyses
were conducted using STATA version 14 [48].
RESULTS
DLBCL patient characteristics

In this study, a majority of DLBCL patients were
white (87.9%) and resided in metro areas (83.0%).
A higher proportion of DLBCL patients were
females (55.5%), lived in West region (43.2%), and
were ≥75 years of age (55.2%). There were some
differences in baseline demographic characteristics
between DLBCL and noncancer patients. Before
adjusting with IPTW, DLBCL patients had a higher
percentage of males, Whites, and those above
75 years of age, compared with noncancer patients
(see Appendix 1).
Hurdle model: impact of DLBCL on any visit to
PCP and number of PCP visits

A higher proportion of DLBCL patients visited
PCPs compared with noncancer patients, which
increased during the DLBCL treatment period
(Table 1). Figure 3 displays the differences in any
visit to a PCP between DLBCL patients and those
without cancer from T1 to T6. Figure 4 summarizes the differences in the predicted number of
PCP visits between the DLBCL and noncancer
patients. Without any adjustments for chronic
conditions, the average number of visits to a PCP
were higher among those with DLBCL compared
with the noncancer patients (T1: 3.57 vs. 3.46; T2:
4.29 vs. 3.44; T3: 8.36 vs. 3.55; T4: 5.12 vs. 3.61;
T5: 4.41 vs. 3.63; T6: 4.50 vs. 3.82). After adjusting for the presence of chronic conditions at each
time period, DLBCL patients still had a higher predicted number of PCP visits compared with noncancer patients (T1: 5.00 vs. 3.27; T2: 4.86 vs. 3.42;
T3: 5.28 vs. 3.45; T4: 4.99 vs. 3.53; T5: 4.73 vs.
3.53; T6: 4.48 vs. 3.54).
From the unadjusted Model 1, DLBCL patients
were more likely to visit PCPs (AOR = 1.39, 95%
CI = [1.32, 1.46]) and had more PCP visits (β = 0.428,
SE = −0.015) than noncancer patients. The regression coefficients for PCP visits remained the same
after adjusting for the demographic characteristics in
Model 2. However, the addition of chronic conditions as covariates in Model 3 considerably reduced
the regression coefficients for any PCP visit (AOR
[95% CI] = 1.24 [1.18, 1.31]) and number of PCP visits (β [SE] = 0.382 [−0.015]), indicating their importance in accounting for PCP visits. After adjusting for
all the SEM covariates in Model 4, the coefficients
remained identical to those found in Model 3.
page 391 of 399

ORIGINAL RESEARCH

Table 1 | Description of Any Visit to Different Provider Specialties During T1–T6 Among Elderly Medicare Beneficiaries with Diffuse Large
B-Cell Lymphoma (DLBCL) and Noncancer Patients

T1

T2

Primary care physician
Cardiologist
Endocrinologist
Mental health specialist
Pulmonologist
Rheumatologist

75.3
70.2
7.6
34.9
25.8
18.1

84.1
62.8
7.0
30.6
23.7
14.3

Primary care physician
Cardiologist
Endocrinologist
Mental health specialist
Pulmonologist
Rheumatologist

75.1
64.5
6.1
31.1
22.6
11.0

75.5
54.9
5.3
33.9
17.7
7.9

T3
DLBCL patients (%)
92.3
83.7
8.8
31.7
34.1
8.7
Noncancer patients (%)
82.2
51.9
5.1
30.6
15.2
7.5

T4

T5

T6

81.4
50.7
6.6
36.7
18.5
7.4

80.5
46.0
6.0
32.2
15.2
7.1

81.0
46.6
6.1
37.1
14.0
6.7

75.7
46.4
4.7
33.9
13.3
6.3

77.3
45.3
4.5
35.6
12.8
6.1

77.9
44.6
4.8
32.6
12.1
5.6

Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003–2011. Percentages represent patients with any visit to the physician during T1–T6. Any visit
to other medical specialist was analyzed only among patients with the corresponding chronic condition (e.g., any visit to endocrinologists was analyzed among those with
diabetes). T1: baseline; T2: prediagnosis; T3: treatment; T4: posttreatment; T5: short follow-up; T6: long follow-up.

Fig. 3 | Differences in any visit to primary care physician and other medical specialists between elderly Medicare beneficiaries with DLBCL
and no cancer. SEER-Medicare 2003–2011. Based on the differences in percentages of patients with any visit to provider between DLBCL
and noncancer patients. T1: baseline; T2: prediagnosis; T3: treatment; T4: posttreatment; T5: short follow-up; T6: long follow-up. DLBCL
diffuse large B-cell lymphoma.

SEM independent variables and any visit to
PCP and number of PCP visits

The following SEM variables were associated with
higher odds of any PCP visit (AOR [95% CI]) and
higher number of PCP visits (β [SE]): Females compared with males (AOR [95% CI] = 1.38 [1.32, 1.45];
β [SE] = 0.067 [−0.010]), patients with age ≥80
compared with those aged 66–69 years (AOR [95%
CI] = 1.31 [1.23, 1.39]; β [SE] = 0.145 [−0.013]),
other racial minorities compared with non-Hispanic Whites (AOR [95% CI] = 1.24 [1.13, 1.36]; β
[SE] = 0.077 [−0.021]), those living in South compared with North-East (AOR [95% CI]=1.55 [1.42,
1.70]; β [SE] = 0.072 [−0.018]), and those having arthritis (AOR [95% CI] = 1.57 [1.50, 1.64]; β
[SE] = 0.190 [−0.009]), heart disease (AOR [95%

CI] = 1.51 [1.45, 1.57]; β [SE] = 0.333 [−0.010]),
respiratory conditions (AOR [95% CI] = 1.46 [1.39,
1.54]; β [SE] = 0.227 [−0.011]), mental health
conditions (AOR [95% CI] = 2.23 [2.08, 2.40]; β
[SE] = 0.333 [−0.013]), or diabetes (AOR [95%
CI] = 1.82 [1.74, 1.91]; β [SE] = 0.202 [−0.010]) compared with those without arthritis, heart disease,
respiratory conditions, mental health conditions,
or diabetes, respectively. Those living in counties
with more hospitals (AOR [95% CI] = 0.90 [0.83,
0.98]; β [SE] = −0.039 [−0.017]) and higher average
travel times (AOR [95% CI] = 0.83 [0.76, 0.89]; β
[SE] = −0.061 [−0.016]) were less likely to have any
PCP visit and had fewer PCP visits compared with
counties with less hospitals and lower average travel
times, respectively.
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Fig. 4 | Unadjusted and adjusted differences in average number of visits to primary care physicians between elderly Medicare beneficiaries
with diffuse large B-cell lymphoma and no cancer. SEER-Medicare 2003–2011. Calculated among those with at least one primary care
physician visit. T1: baseline; T2: prediagnosis; T3: treatment; T4: posttreatment; T5: short follow-up; T6: long follow-up.
Table 2 | Unadjusted and Adjusted Estimates from Negative Binomial Regressions with Generalized Estimating Equation on Number of Visits
to Primary Care Physicians (PCPs) Among Elderly with Diffuse Large B-Cell Lymphoma (DLBCL) Using Inverse Probability Treatment Weights

Model 1
β

Model 2

SE

p

β

SE

p

<.0001
<.0001
<.0001
<.0001
<.0001

Ref.
0.134
0.491
0.027
−0.121
−0.108

−0.016
−0.028
−0.022
−0.020
−0.022

<.0001
<.0001
.209
<.0001
<.0001

Time
Baseline, T1
Prediagnosis, T2
Treatment, T3
Posttreatment, T4
Short follow-up, T5
Long follow-up, T6

Ref.
0.201
0.872
0.337
0.188
0.220

−0.017
−0.020
−0.020
−0.020
−0.020

Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003–2011. Model 1: unadjusted; Model 2: adjusted for age, sex, race, region, rural/urban, marital
status, arthritis, diabetes, any heart condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, DLBCL stage, radiotherapy, chemotherapy, immunotherapy, stem cell transplant, county% black, county% hospitals, county% without health insurance, and county% below high-school education.
SE standard errors.

Figure 3 displays the differences in any visit to other
medical specialists between DLBCL patients and
those without cancer from T1 to T6. From unadjusted analyses, a higher percentage of DLBCL
patients visited cardiologists, endocrinologists, pulmonologists, and rheumatologists compared with
noncancer patients (Table 1). However, with regard
to mental health specialists, we did not observe
a clear pattern of use among DLBCL patients.
After adjusting for all the SEM covariates, DLBCL
patients were more likely to visit cardiologists (AOR
[95% CI] = 1.40 [1.32, 1.47]), endocrinologists (1.43
[1.21, 1.70]), and pulmonologists (1.50 [1.36, 1.67])
than patients with no cancer.

compared with those without heart conditions or
mental health conditions, respectively. Older adults
with any heart condition (1.62 [1.45, 1.81]), mental
health conditions (1.31 [1.19, 1.44]), or diabetes (1.11
[1.01, 1.22]) were more likely to have any visit to pulmonologists than those without any heart condition,
mental health conditions (depression or anxiety), or
diabetes, respectively. Also, females compared with
males (0.75 [0.71, 0.79]), African Americans compared with Whites (0.76 [0.69, 0.85]), those living in
the North-Central (0.83 [0.74, 0.92]) or West (0.78
[0.71, 0.85]) region compared with North-East, and
those living in rural areas (0.80 [0.73, 0.89]) compared with metro areas were less likely to have any
visit to cardiologists.

SEM-independent variables and any visit to
other medical specialties

Change in number of PCP visits over
time in DLBCL patients

Those with arthritis (AOR [95% CI] = 1.09 [1.04,
1.14]), asthma (1.18 [1.13, 1.24]), mental health conditions (1.39 [1.31, 1.47]), or diabetes (1.17 [1.12,
1.23]) were more likely to have any visit to cardiologists compared with those without arthritis, asthma,
mental health conditions, or diabetes, respectively.
Older adults with heart conditions (1.31 [1.14, 1.50])
or mental health conditions (1.23 [1.08, 1.40]) were
more likely to have any visit to endocrinologists

The results from the negative binomial regressions
for change in PCP visits among DLBCL patients are
displayed in Table 2. From unadjusted analysis in
Model 1, the number of PCP visits increased from
baseline (T1) to prediagnosis (T2), treatment (T3),
posttreatment (T4), and follow-up periods (T5 and
T6). However, after adjusting for SEM covariates in
Model 2, we observed that the number of PCP visits
increased from baseline (T1) to prediagnosis (T2)

Impact of DLBCL on any visit to other medical specialists

TBM
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and treatment (T3) periods and decreased during
the follow-up periods (T5 and T6).
SEM-independent variables and number
of PCP visits in DLBCL patients

Factors associated with a higher number of visits to
PCPs among DLBCL patients included age ≥80 years
compared with 66–69 years (β [SE] =0.082 [0.025]),
females compared with males (0.059 [0.017]), and
those living in the South (0.089 [0.032]), NorthCentral (0.139 [0.033]), or West (0.100 [0.027])
region compared with North-East. Presence of
chronic conditions was the strongest predictor of having a higher number of PCP visits among DLBCL
patients. DLBCL patients with arthritis had 48%
higher, diabetes had 62% higher, any heart condition had 97% higher, depression or anxiety had
111% higher, and asthma or COPD had 48% higher
number of PCP visits during 6 months compared
with DLBCL patients without arthritis, diabetes, any
heart condition, depression or anxiety, and asthma
or COPD, respectively (see Appendix 2).
With respect to DLBCL treatments, those receiving radiotherapy (0.085 [0.023]) or immunotherapy
(0.099 [0.028]) had a higher number of PCP visits
compared with those not receiving radiotherapy or
immunotherapy, respectively. Those receiving stem
cell transplants (−0.060 [0.017]) had a lower number
of PCP visits than those not receiving stem cell transplant. With respect to community factors, those living
in counties with a lower number of health-insured
individuals (−0.074 [0.033]) and higher number of
Blacks (-0.093 [0.032]) had a lower number of PCP
visits than those living in counties with a higher
number of health-insured individuals and a higher
number of Blacks. Also, older adults living in counties with a lower education level (0.118 [0.031]) had
a higher number of PCP visits than those living in
counties with a higher education level.
DISCUSSION

In this first study of its kind, we examined the impact of newly diagnosed DLBCL on visits to different provider specialties to understand the challenges
for care coordination. We analyzed the impact of
DLBCL on any PCP visit, the number of PCP visits,
and any visit to other medical specialists by using a
robust study design that compared DLBCL patients
with cancer-free patients. Our study findings indicated that DLBCL patients were more likely to visit
PCPs and had higher number of PCP visits compared with those without any cancer, even after
adjusting for intrapersonal, healthcare system, and
community factors. These findings are consistent
with a previous study in breast cancer patients who
had higher PCP visits than noncancer patients [18].
We found that DLBCL patients were more
likely to visit other medical specialists compared
with noncancer patients. This is a unique finding

because none of the published studies examined
the relationship between cancer diagnosis and visits
to other medical specialists, a key indicator of the
need for care coordination. This finding suggests
problems for care coordination for patients enrolled
in fee-for-service Medicare because Medicare does
not compensate the providers for communicating with other providers for care coordination.
Providers have to face many challenges even with
the availability of electronic health records due to
a lack of interoperability between electronic health
information systems [49].
With respect to change in PCP visits, our study
findings are somewhat consistent with previous
studies in colorectal and breast cancer patients, who
were found to increase in their visits to PCP during
the posttreatment period (i.e., 1 year after cancer
diagnosis) [18–21]. Our study results indicated that
the PCP visits increased threefold during the treatment period. One possible explanation for more
visits to PCPs and other medical specialists among
DLBCL patients is the presence of multiple chronic
conditions. We observed that DLBCL patients had
higher prevalence of diabetes, arthritis, any heart
condition, depression or anxiety, and asthma or
COPD than noncancer patients. Our findings also
indicated that many patients were newly diagnosed
with chronic conditions after DLBCL diagnosis and
treatment, which statistically explained the increase
in the number of PCP visits over time. Further,
patients’ pre-existing chronic conditions may have
worsened due to DLBCL treatment. These results
suggest that acute medical care for newly diagnosed
conditions and increased care for pre-existing conditions may have escalated visits to PCPs.
The presence of multiple chronic conditions may
also explain the higher visits to specialists among
patients with unrelated comorbidity, such as higher
visits to endocrinologists by mental health patients.
Also, the chemotherapy and stem cell transplant
are associated with significant side effects such as
cardiotoxicity [50] and loss of bone density [51].
These side effects may be another reason for the
increase in visits to specialists during the treatment
period. This sharp increase in provider visits poses
significant challenges to care coordination. DLBCL
patients may face greater difficulties in care coordination because the roles of PCPs and other medical
specialists have not been properly defined during
the cancer treatment period [52, 53]. It is often
unclear who should be responsible for such problems as cardiotoxicity or other vague symptoms during the treatment phase, which could be side effects
of treatment, exacerbation of chronic conditions, or
acute illness.
Surprisingly, we did not find a significant difference in visits to mental health providers among older
adults diagnosed with both DLBCL and mental
health conditions compared with those without
any cancer, after adjusting for time, index year, and
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other SEM factors. As the diagnosis and treatment
of DLBCL lead to significant long-term psychiatric
morbidity such as anxiety, depression, posttraumatic
stress disorder, and lower health status [54–56], it
is concerning that DLBCL patients’ visits to mental
health providers did not change. PCPs and oncologists may need to refer older adults with DLBCL
diagnosed with mental health conditions to suitable
mental health providers when necessary.
Further research is required on the reasons for
the low number of visits to mental health specialists
by DLBCL patients with mental health conditions.
Such studies and future policy efforts may help in
increasing DLBCL patients’ visits to mental health
specialists, when necessary. It is also important for
the PCPs, other medical specialists, and oncologists
to communicate about the DLBCL patients’ ongoing treatments and health status with each other.
Future studies are needed to examine whether
DLBCL patients face difficulties in communication
among their providers because of a sudden increase
in visits during the DLBCL treatment period. New
modes of interprofessional communication could result in improved health outcomes.
Another critical area for research is the interventions to improve care coordination for cancer
patients. It is important to investigate whether
the strategic frameworks developed by the U.S.
Department of Health and Human Services [16]
and the National Quality Forum [17] can be implemented in the context of cancer care and can improve care coordination for older adults with cancer
and multiple chronic conditions. Another measure
for improving the care coordination between oncologists and PCPs is the use of survivorship care
plans. In response to the National Academy of
Medicine’s (formerly Institute of Medicine) report
on cancer survivorship, many groups have developed specific care plans for cancer patients [57, 58].
Another effective method is to provide reimbursement for improving care coordination. For example,
Medicare recently added a fee code that reimburses
physicians for providing care coordination services.
Recent studies have shown that a shared electronic medical record (EMR) system such as in the
Veterans Administration health system can be helpful for improving the communication between PCP,
other specialists, and oncologists [59]. Interventions
to increase direct communication through fax, telephone, or e-mail, rather than relying on the patient
may also be successful in improving care coordination. The effectiveness of these interventions
in improving care coordination can be measured
through patient or provider satisfaction surveys [60].
Transfer of information such as patient’s medical
history, treatment, or lab results from one physician
to other can also be measured to assess good care
coordination [60].
Our study findings should be interpreted in the
context of some limitations. We used the HCFA
TBM

provider specialty codes given in the Physician/
Supplier Claims file (NCH) of the SEER-Medicare
dataset to identify the provider specialties in this
study. Although the HCFA codes have been used
in previous studies on older adults with cancer [40,
61, 62], these codes may not capture all the visits
to different provider specialties [63]. For example,
DLBCL patients may have received mental health
care from social workers or other behavioral practitioners. These specialties are not included in the
HCFA codes, and hence, we could not measure
them in this study. The purpose of our study was to
examine the burden and opportunities for care coordination during the different phases of care among
older adults with DLBCL. We did not investigate
the actual provider–provider interaction or patients’
and providers’ experiences of care coordination in
this study. Only the first diagnosis of DLBCL was
analyzed in our study as the index date. We did not
include a recurrence or relapse of DLBCL as it may
not be identified reliably. Our study results can be
generalized to Medicare fee-for-service beneficiaries
who resided in SEER regions only. Another limitation of our study results is time-dependent confounding by DLBCL treatment [64]. Although DLBCL
treatments and chronic conditions were repeatedly
measured in this study, possible change in treatment
side effects over time may have affected provider visits. Lastly, we estimated the population-averaged impact of some SEM factors on provider visits. Hence,
our study results with these factors (e.g., county-wide
educational level) should not be used to design
care coordination interventions to target individual
patients’ risk characteristics.
The strengths of our study include the use of
SEER-Medicare database with nationally representative data to examine the care of older adults
with newly diagnosed cancer. We examined the
visits to other medical specialists over a 3-year
time period spanning the cancer diagnosis, treatment, and follow-up periods that had not been
analyzed before. We used a comprehensive SEM
framework to examine the association of various
personal and contextual factors with the visits to
different provider specialties among older adults
with DLBCL. Further, we utilized a robust study
design with a noncancer comparison group and
time-varying diagnosis of chronic conditions in
our study.
CONCLUSIONS

The elderly Medicare beneficiaries with DLBCL
were more likely to visit PCPs or other medical
specialists and had higher number of visits to PCPs
compared with noncancer patients. The side effects
of aggressive DLBCL treatment and more frequent
contact with healthcare system may have led to
increased diagnosis of other chronic conditions,
which partially explained the higher visits to PCPs
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and specialists. The time period immediately after
DLBCL diagnosis needs to be targeted to implement interventions to improve care coordination
between the oncologist, PCP, and other medical
specialists.
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Appendix 1 | Description of Selected Characteristics of Elderly Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) and Noncancer
Patients Before and After Inverse Probability Treatment Weights

DLBCL

All
Age (years)
66–69
70–74
75–79
≥80
Sex
Female
Male
Race/Ethnicity
White
African American
Hispanic
Others
Geographic region
North-East
South
North-Central
West
Rural/Urban
Metro
Urban
Rural
Index year
2003
2004
2005
2006
2007
2008
2009
2010
2011

Noncancer

N

%

N

%

5,455

27.0

14,770

73.0

1,071
1,374
1,373
1,637

19.6
25.2
25.2
30.0

4,452
3,914
2,786
3,618

30.1
26.5
18.9
24.5

3,029
2,426

55.5
44.5

9,479
5,291

64.2
35.8

4,796
190
120
349

87.9
3.5
2.2
6.4

11,885
1,217
379
1,289

80.5
8.2
2.6
8.7

Sig.

DLBCL

Noncancer

Col. wt %

Col. wt %

27.0

73.0

27.3
26.4
20.6
25.7

27.3
26.2
20.6
25.9

62.2
37.8

61.9
38.1

82.1
7.2
2.5
8.1

82.5
7.0
2.5
8.1

<.001

<.001

<.001

<.001
1,113
1,267
720
2,355

20.4
23.2
13.2
43.2

2,885
3,779
1,752
6,354

19.5
25.6
11.9
43.0

20.0
24.8
12.1
43.2

19.8
25.0
12.2
43.1

4,525
815
115

83.0
14.9
2.1

12,172
2,278
320

82.4
15.4
2.2

83.3
14.7
2.0

82.3
15.5
2.2

584
589
586
584
610
609
623
624
646

10.7
10.8
10.7
10.7
11.2
11.2
11.4
11.4
11.8

1,255
1,349
1,280
1,432
1,569
1,653
1,888
2,052
2,292

8.5
9.1
8.7
9.7
10.6
11.2
12.8
13.9
15.5

9.0
9.8
9.4
10.3
10.7
11.3
12.3
13.1
14.2

9.1
9.6
9.3
10.0
10.8
11.2
12.4
13.2
14.5

<.001

Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003–2011. Based on 5,455 Medicare beneficiaries with DLBCL and a random sample of 14,770
beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived with using inverse probability treatment weights.
Sig. significance level; wt weighted.
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Appendix 2 | Adjusted Estimates from Negative Binomial
Regression with Generalized Estimating Equation on Number of PCP
Visits with Inverse Probability Treatment Weights Among Elderly
with Diffuse Large B-Cell Lymphoma

β
Time
Baseline, T1
Prediagnosis, T2
Treatment, T3
Posttreatment, T4
Short follow-up, T5
Long follow-up, T6
Age groups
66–69
70–74
74–79
≥80
Sex
Female
Male
Race
Whites
African American
Hispanics
Others
Marital status
Single
Married
Separated/Divorced/
Others
Region
North-East
South
North-Central
West
Rural/Urban
Metro
Urban
Rural
DLBCL stage
Stage I
Stage II
Stage III
Stage IV
Radiotherapy
Yes
No
Chemotherapy
Yes
No
Immunotherapy
Yes
No

TBM

Number of PCP visits
SE

p

Ref.
0.133
0.491
0.027
−0.121
−0.108

0.016
0.028
0.022
0.02
0.022

<.001
<.001
.209
<.001
<.001

Ref.
0.041
0.046
0.082

0.024
0.025
0.025

.087
.063
.001

0.017

.001

0.059
Ref.
Ref.
−0.065
0.070
0.065

0.04
0.055
0.033

.112
.202
.056

Ref.
−0.049
-0.036

0.037
0.039

.196
.362

Ref.
0.089

0.032

.003

0.139
0.100

0.033
0.027

<.001
<.001

Ref.
0.044
0.005

0.027
0.056

.065
.854

Ref.
−0.020
−0.007
0.030

0.023
0.025
0.021

.382
.808
.145

0.085
Ref.

0.023

<.001

−0.025
Ref.

0.024

.295

0.099
Ref.

0.028

<.001

Appendix 2 | Continued

Stem cell transplant
Yes
−0.060
No
Ref.
Arthritis
Yes
0.171
No
Ref.
Diabetes
Yes
0.209
No
Ref.
Any heart condition
Yes
0.295
No
Ref.
Depression/Anxiety
Yes
0.324
No
Ref.
Asthma/COPD
Yes
0.170
No
Ref.
County% blacks
1.14
Ref.
4.21
−0.059
9.46
−0.007
28.38
−0.093
County% hospitals
0.56
Ref.
0.96
0.024
1.30
−0.001
3.48
−0.038
County% without health insurance
12.89
Ref.
17.21
0.015
22.07
−0.048
28.24
−0.074
County average travel time
19.50
Ref.
24.09
−0.037
27.42
−0.010
31.06
−0.050
County% less than high-school education
8.27
11.99
0.039
15.75
0.082
24.52
0.118

0.017

.001

0.016

<.001

0.016

<.001

0.016

<.001

0.021

<.001

0.017

<.001

0.025
0.03
0.032

.051
.931
.005

0.025
0.024
0.028

.145
.930
.146

0.025
0.03
0.033

.468
.126
.048

0.023
0.025
0.027

.104
.632
.043

0.024
0.028
0.031

.137
.008
<.001

Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003–2011.
Based on 5,455 Medicare beneficiaries with DLBCL who had at least one PCP visit
during T1 to T6. Adjusted beta coefficients and standard errors are from generalized
estimating equation with negative binomial distribution and unstructured correlation matrix.COPD chronic obstructive pulmonary disease; DLBCL diffuse

large B-cell lymphoma; PCP primary care physician.
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